AbbVie Inc (ABBV)
Debt-to-assets ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total assets | US$ in thousands | 135,161,000 | 134,711,000 | 138,805,000 | 146,529,000 | 150,565,000 |
Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $135,161,000K
= 0.00
The debt-to-assets ratio for AbbVie Inc has remained consistent at 0.00 from December 31, 2020, to December 31, 2024. This ratio indicates that the company has not used any debt to finance its assets during this period. A low debt-to-assets ratio suggests that AbbVie Inc relies more on equity financing, which can be favorable as it indicates lower financial risk and potentially more financial flexibility. However, it is important to consider other financial metrics and industry benchmarks to gain a comprehensive understanding of the company's financial health and stability.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-assets ratio
AbbVie Inc
ABBV
0.00
Abbott Laboratories
ABT
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.39
ANI Pharmaceuticals Inc
ANIP
0.00
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.09
Bristol-Myers Squibb Company
BMY
0.51
Catalyst Pharmaceuticals Inc
CPRX
0.00
Collegium Pharmaceutical Inc
COLL
0.00